Action IVCP SWIFTMERGE ACQUISITION CORP.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Autres langues Swiftmerge Acquisition Corp.

Actions

IVCP

KYG638361033

Marché Fermé - Nasdaq
Autres places de cotation
 21:59:21 17/05/2024 		Varia. 5j. Varia. 1 janv.
10,84 USD -0,09 % Graphique intraday de Swiftmerge Acquisition Corp. +0,09 % -0,28 %
01/04 Swiftmerge Acquisition Corp. annonce ses résultats pour l'exercice clos le 31 décembre 2023 CI
2023 Swiftmerge Acquisition Corp. annonce ses résultats pour le troisième trimestre et les neuf mois clos le 30 septembre 2023 CI

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
Swiftmerge Acquisition Corp. Reports Earnings Results for the Full Year Ended December 31, 2023
Swiftmerge Acquisition Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Swiftmerge Acquisition Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Swiftmerge Acquisition : Non-Reliance on Previously Issued Financial Statements or Related Audit Report or Completed Interim Report - Form 8-K
Swiftmerge Acquisition Signs Merger Deal to Take HDL Therapeutics Public
HDL Therapeutics to Go Public in Merger with Swiftmerge Acquisition Corp.
SWIFTMERGE ACQUISITION CORP. : Entry into a Material Definitive Agreement, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits (form 8-K)
Swiftmerge Acquisition : Adjournment of Extraordinary General Meeting - Form 8-K
Swiftmerge Acquisition Corp. Reports Earnings Results for the First Quarter Ended March 31, 2023
SWIFTMERGE ACQUISITION CORP. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
HDL Therapeutics Inc Plans to Become Publicly Traded via a Business Combination With $225 Million Swiftmerge (NASDAQ: IVCP) With Goal to Transform Cardiovascular Disease Treatment
HDL Therapeutics, Inc. signed a non-binding letter of intent to acquire Swiftmerge Acquisition Corp. in a reverse merger transaction.
SWIFTMERGE ACQUISITION CORP. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
SWIFTMERGE ACQUISITION CORP. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K)
Swiftmerge Acquisition Corp. Reports Earnings Results for the Full Year Ended December 31, 2022
Swiftmerge Acquisition Corp. Auditor Raises 'Going Concern' Doubt
Swiftmerge Acquisition Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
SWIFTMERGE ACQUISITION CORP. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)
SWIFTMERGE ACQUISITION CORP. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)
Swiftmerge Acquisition Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action IVCP
  4. Actualités Swiftmerge Acquisition Corp.
  5. Autres langues